Cipla Ltd

Meeting Details

• Board meeting scheduled for Tuesday, 27 October 2026.
• Time: not disclosed; location not disclosed.

Key Agenda Items

• Consider unaudited standalone and consolidated results for quarter and half year ended 30 September 2026.

Other Notes

• Trading window closed from 1 October 2026 to 29 October 2026 for financial results.

Share Capital Update

• Allotted 12,168 fully paid-up equity shares of INR 2 each under ESOS 2013-A and ESAR 2021.
• Date of allotment: 24 September 2026.
• Capital now INR 1,61,57,41,230 with 80,78,70,615 equity shares.

Senior management transition

• Change type: Cessation of Senior Management Personnel at Cipla Ltd.
• Person: Mr. Venkata Sai Mungara; former Global Head Supply Chain.
• New role: Chief of Manufacturing and Supply Chain Operations, Cipla USA Inc.
• Effective date: 1 October 2026.
• Reason: Transition to subsidiary role.
• Cipla Ltd will cease to be Senior Management Personnel.

ESG rating update

• Cipla assigned an ESG rating of 68 by Niche.
• Niche communicated the rating to NSE on 11 September 2026 and to BSE on 17 September 2026.
• Cipla has not received any direct communication from Niche regarding the rating.
• Cipla became aware of the rating via BSE alert on 17 September 2026.

Partnership details

• Exclusive US licensing and supply of QL2107, a Keytruda biosimilar.
• Qilu to develop, obtain regulatory approval, and supply; Cipla USA to commercialize.
• Aims to expand Cipla's oncology biosimilars portfolio; improve access.
• Launch subject to regulatory approvals.

Scheme of Amalgamation update

• NCLT order dated 18 August 2026 approves Scheme of Amalgamation by Absorption of Inzpera Healthsciences into Cipla.
• Notices to shareholders and creditors issued electronically or physically under Regulation 30 and NCLT order.
• Representations may be filed with Hon'ble NCLT within 30 days, copy to Cipla.
• Dispensation of meetings for equity shareholders and unsecured creditors of Transferee per NCLT order.
• No secured creditors in Transferee; no meeting of secured creditors required.
• Notice and Scheme/NCLT Order available on Cipla website through links.
• Representations to be submitted within 30 days; no response presumed no objection.
• Company Secretary: Rajendra Chopra, ICSI Membership No: A12011, authorised signatory.
• Transferor: Inzpera Healthsciences Limited; Transferee: Cipla Limited.
• Date: 3 September 2026.

Key terms

• Exclusive license and supply to Cipla for TQB2102 in India, South Africa, and five emerging markets.

Development and roles

• Cipla to lead local clinical development, regulatory activities, and commercialization; CTTQ to manufacture and supply.

Outlook and impact

• Collaboration aims to accelerate development and access subject to regulatory approvals.

Agreement overview

• Exclusive license and supply agreement for Rolditamig Deuderuxtecan (TQB2102) between Cipla and SBP Group.
• Cipla gains exclusive development, regulatory, and commercialization rights in India, South Africa and five other emerging markets.
• CTTQ will manufacture and supply TQB2102; Cipla handles local development, regulatory, and commercialization.
• TQB2102 is being evaluated across HER2-expressing cancers with potential best-in-class profile.
• The collaboration aims to accelerate development and patient access in licensed territories.

Overview

• USFDA inspection at InvaGen Unit 3, Central Islip, NY, classified as Voluntary Action Indicated (VAI).
• Facility is a wholly owned Cipla subsidiary; USFDA communication dated 28 August 2026.

Timeline

• Inspection conducted 13–17 July 2026 (EDT).
• USFDA classification communicated on 28 August 2026.

Impact

• No financial figures disclosed in the update.
• No governance changes or management actions announced.